Shionogi, Inc

India's new drugs aim to combat antibiotic-resistant superbugs, with Enmetazobactam and Zaynich showing promise. Antibiotic resistance caused 1.14 million deaths globally in 2021, with India facing significant challenges. Innovative drugs and better prescription practices are crucial to address this growing threat.

Shionogi announced that its Phase 3 study, SCORPIO-PEP, met its primary endpoint. Ensitrelvir significantly reduced symptomatic SARS-CoV-2 infection in household contacts compared to placebo, with no new safety concerns.

The article discusses the importance of enabling JavaScript for optimal app performance.

Despite 16 new antibacterial drugs approved since 2017 and 97 more in development, superbugs continue to evolve faster than treatments can be developed. Organizations like CARB-X are funding unconventional approaches, including phage therapy and synthetic antimicrobials, to combat antimicrobial resistance. However, the lack of private investment and slow legislative action hinder progress, emphasizing the urgent need for increased funding and recognition of the threat posed by superbugs.

DelveInsight's 'Respiratory Syncytial Virus Pipeline Insight, 2024' report details 50+ companies developing 50+ therapies, including Nirsevimab, Sisunatovir, and RSVpreF, across various stages of clinical trials. Key companies include GSK, Pfizer, and Sanofi, with recent successes like GSK's Arexvy vaccine and MSD's clesrovimab. The report covers mechanism of action, route of administration, and market dynamics.

Fetroja® (cefiderocol) treats cUTIs and HABP/VABP in adults caused by specific Gram-negative bacteria. It is contraindicated in severe hypersensitivity to cefiderocol or other beta-lactam drugs. Fetroja may increase mortality in carbapenem-resistant infections and cause hypersensitivity reactions, CDAD, seizures, and CNS adverse reactions. It should be used to treat proven or strongly suspected bacterial infections to prevent drug resistance.

The 'Antibiotic Resistance Markets - Therapeutics by Pathogen and Therapy Type' report outlines market players addressing antimicrobial resistance, including drug manufacturers, biotech companies, and regulatory bodies. It highlights the role of diagnostics in combating AMR and identifies 6 key market opportunities. The report provides five-year market forecasts and profiles over 100 biotech companies.

ViiV Healthcare plans to triple its HIV prevention therapy supply at not-for-profit prices in low- and middle-income countries by 2026, committing to 2 million doses of long-acting cabotegravir for pre-exposure prophylaxis. This move aims to accelerate HIV prevention in resource-limited, high-burden countries.

Nxera Pharma Japan partners with Shionogi for Quviviq distribution and sales in Japan, following the drug's approval for treating adult insomnia. Shionogi replaces Mochida Pharmaceutical, taking full responsibility for sales and distribution.